E
Endeavor BioMedicines
Clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis
About Endeavor BioMedicines
Endeavor BioMedicines is a biotech startup that operates in the healthcare sector, specifically in the development of targeted therapies for terminal diseases such as fibrosis and cancer. Their primary goal is to improve the quality of life and longevity of patients suffering from these conditions.
The company's business model revolves around the research, development, and commercialization of innovative, best-in-class medicines. They use a data-driven approach, leveraging the extensive experience of their team in the biotech and clinical development fields. This allows them to create targeted treatments that are more effective and have fewer side effects than traditional therapies.
Endeavor BioMedicines serves a broad range of clients, primarily patients suffering from terminal diseases. However, their market also includes healthcare providers and institutions that administer their treatments, as well as insurance companies that cover the cost of these therapies.
The company generates revenue through the sale of their developed drugs. This typically involves a lengthy process of research and development, followed by clinical trials, and finally, if successful, commercial sale. The profitability of the company is therefore dependent on the successful development and approval of their drugs.
In summary, Endeavor BioMedicines is a patient-focused biotech company that uses a data-driven approach to develop targeted therapies for terminal diseases, with the aim of improving patient outcomes and quality of life.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2024 | $133M | $530M | Fidelity Investments · Invus · Matrix Capital Management · T. Rowe Price | ↗ |
| SERIES BOther financing | Feb 2022 | $101M | $404M | Tekla Capital Management · Omega Funds · T. Rowe Price · Piper Heartland Healthcare Capital | ↗ |
Growth signals
Latest recorded traffic for Endeavor BioMedicines is 3.6K monthly website visits, up 71.4% over the last three months. Endeavor BioMedicines's team grew 4.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Endeavor BioMedicines in the San Diego ecosystem
The Endeavor BioMedicines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Longitude CapitalOmega Funds
Ally Bridge Group- TMTekla Capital Management
T. Rowe Price- PCPiper Heartland Healthcare Capital
Perceptive Advisors
Revelation Partners
Avidity Partners
Series B and later9 investors entered at this stage
Fidelity Investments
Invus
Matrix Capital Management- SBSilver Arch Bio
Woodline Partners
Velosity Capital
Aberdeen
SymBiosis
Eckuity
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Endeavor BioMedicines on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Endeavor BioMedicines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









